- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Lipids
Volume 2012 (2012), Article ID 304292, 22 pages
A Pleiotropic Role for the Orphan Nuclear Receptor Small Heterodimer Partner in Lipid Homeostasis and Metabolic Pathways
1Section of Endocrinology, Department of Emergency and Organ Transplantations, University of Bari “Aldo Moro” Medical School, Piazza G. Cesare 11, 70124 Bari, Italy
2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Edward Doisy Research Center, Saint Louis University School of Medicine, 1100 S. Grand Boulevard, Room 205, St. Louis, MO 63104, USA
3Department of Biomedical Sciences and Human Oncology, Clinica Medica “A. Murri”, University of Bari Medical School, Piazza G. Cesare 11, 70124 Bari, Italy
Received 8 August 2011; Accepted 5 December 2011
Academic Editor: B. A. Neuschwander-Tetri
Copyright © 2012 Gabriella Garruti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Nuclear receptors (NRs) comprise one of the most abundant classes of transcriptional regulators of metabolic diseases and have emerged as promising pharmaceutical targets. Small heterodimer partner (SHP; NR0B2) is a unique orphan NR lacking a DNA-binding domain but contains a putative ligand-binding domain. SHP is a transcriptional regulator affecting multiple key biological functions and metabolic processes including cholesterol, bile acid, and fatty acid metabolism, as well as reproductive biology and glucose-energy homeostasis. About half of all mammalian NRs and several transcriptional coregulators can interact with SHP. The SHP-mediated repression of target transcription factors includes at least three mechanisms including direct interference with the C-terminal activation function 2 (AF2) coactivator domains of NRs, recruitment of corepressors, or direct interaction with the surface of NR/transcription factors. Future research must focus on synthetic ligands acting on SHP as a potential therapeutic target in a series of metabolic abnormalities. Current understanding about the pleiotropic role of SHP is examined in this paper, and principal metabolic aspects connected with SHP function will be also discussed.
Nuclear receptors (NRs) constitute a unique family of ligand-modulated transcription factors. NRs mediate cellular response to small lipophilic endogenous and exogenous ligands [1, 2] and are responsible for sensing a number of hormones, including steroid and thyroid hormones, and act as positive and negative regulators of the expression of specific genes [3–5]. Therefore, NRs play a central role in many aspects of mammalian development, as well as lipid homeostasis, physiology, and metabolism. NRs make up one of the most abundant classes of transcriptional regulators in the body and have emerged as promising pharmaceutical targets.
Classically, NRs consist of several functional domains, that is, a variable N-terminal ligand-independent transactivation domain (which often exhibits a constitutive transcription activation function (AF-1)), a highly conserved DNA-binding domain (DBD) that contains two zinc fingers, a hinge domain (a variable linker region), and a multifunctional C-terminal domain. Furthermore, the C-terminal domain includes the ligand binding (LBD), the dimerization interface, and the ligand-dependent transactivation domain AF-2 [1, 6].
Small heterodimer partner (SHP; NR0B2 for nuclear receptor subfamily 0, group B, member 2; MIM number 604630, 601665) is a member of the mammalian NR superfamily, due to the presence of a putative ligand-binding domain (LBD) . SHP functions as a corepressor through heterodimeric interaction with a wide array of nuclear receptors and repressing their transcriptional activity. SHP achieves its goal via several members of the NR superfamily that are able to regulate SHP expression. However, SHP is also a unique and atypical NR because it lacks the classical DNA-binding domain (DBD), generally present in other NRs . The NR0B family of NRs consists of 2 orphan receptors: SHP and DAX-1 (dosage-sensitive sex reversal adrenal hypoplasia congenita (AHC) critical region on the X chromosome, gene 1). DAX1 is a gene whose mutation causes the X-linked adrenal hypoplasia congenita  and is the only family member that lacks a conventional DBD. DAX-1 (NR0B1) is therefore seen as the closest relative of SHP in the NR superfamily [10–12]. Both SHP and DAX-1 appear to be specific to vertebrates. In this respect, no homologous genes have been found in Drosophila melanogaster or Caenorhabditis elegans . Whereas SHP is different from other conventional NRs both structurally and functionally, it acts as a ligand-regulated receptor in metabolic pathways . SHP belongs to the orphan subfamily since there is no known ligand for this receptor, except for some retinoid-related molecules . SHP inhibits transcriptional activation by working on several other nuclear receptors, that is, directly modulating the activities of conventional nuclear receptors by acting as an inducible and tissue-specific corepressor [12, 15]. The discovery of SHP dates back to 1996 ; since then, this orphan NR has been identified as a key transcriptional regulator of signaling pathways [8, 16] involving fundamental biological functions and metabolic processes. Such processes include cholesterol, bile acid and fatty acid metabolism, glucose and energy homeostasis, and reproductive biology . Experiments performed by fluorescence in situ hybridization (FISH) analysis of the human metaphase chromosome have shown that SHP is found at a single locus on chromosome 1 at position 1p36.1 and consists of two exons and a single intron spanning approximately 1.8 kb with 257 amino acids in humans . In mice and rats, SHP resides on chromosomes 4 and 5, respectively, both consisting of 260 amino acids. SHP expression is predominantly observed in the liver [10, 18], but it is also detected at lower levels in other tissues, including the pancreas, spleen, small intestine, colon, gallbladder, kidney, adrenal gland, ovary, lung, brainstem, cerebellum, heart, and thymus (Table 1) [19–21].
The genomic structure and human SHP domain structure are depicted in Figure 1 . SHP is indeed able to repress the transcriptional activities of its target NRs and transcriptional regulators through two functional Leu-Xaa-Xaa-Leu-Leu- (LXXLL-) like motifs [22–24]. Such motifs appear to be essential for the interaction with the (activation function 2) AF-2 domains of several sets of NRs [22, 23]. The human SHP is enriched by another 12 amino acids [25–36], and this region between helix 6 and 7 is also involved in the repression of the transactivation of NRs .
About half of all mammalian NRs and several transcriptional coregulators can interact with SHP . Since SHP lacks DNA-binding domain, it exerts the inhibitory effects through protein-protein interaction . SHP expression seems to follow a circadian rhythm in the liver, involving the CLOCK-BMAL1 pathway and suggesting that some of the regulatory functions of SHP and deriving functions must be temporal [19, 20, 38].
Gene expression of SHP is regulated by several factors including NRs, transcription factors, and a number of additional conditions and substances, as extensively reported in Table 2. Also, the central role of SHP is clear since this NR is able to act as a coregulator for wide range of targets, namely, NRs/transcription factors/transcriptional coregulators and few different molecules, as depicted in Table 3. In general, SHP acts as a repressor of the transcriptional activity of the specific interacting partner (via LBD of the partner and NR boxes of SHP) [12, 39–43]. However, it is also demonstrated that SHP is able to upregulate gene transcription, as in the case of PPARα and PPARγ [44–46] and NF-κB .
Both N-terminal NR interaction domain and C-terminal domain of SHP are important for repression [47, 48]. Overall, the SHP-mediated repression of target transcription factors occurs by at least three distinct transcriptional repression mechanisms (Figure 2).
A first mechanism involves direct interference with the AF-2 coactivator domain of NRs (competition for coactivator binding, leading to the repression of NR-mediated transcriptional activity). This is the case for the inhibition of estrogen receptor α (ERα) and estrogen receptor β (ERβ) .
A second mechanism for the SHP-mediated repression involves the recruitment of corepressors including direct interactions among mammalian homolog of the Saccharomyces cerevisiae transcriptional corepressor Sin3p (mSin3A), human Brahma (Brm), SWItch/Sucrose NonFermentable (SWI/SNF) complexes leading to the repression of cholesterol 7α-hydroxylase (CYP7A1) ).
A third mechanism of inhibition of SHP involves the direct interaction with the surface of NR or transcription factor, resulting in the blockade of DNA binding and the consequent inhibition of its transcriptional activity. This is the case for RAR-RXR heterodimers , PXR-RXR binding to DNA by SHP , interaction with hepatocyte nuclear factor (HNF4), or Jun family of the activator protein 1 (AP-1) transcription factor complex (JunD) [51, 52].
All three mechanisms might occur sequentially or alternatively according to type of cells and promoters .
Clearly, information on factors that increase or decrease SHP expression and that are regulated by SHP is essential for understanding the regulatory effects of this orphan NR. Few years of research have not been enough to identify a true ligand. Interestingly, it is suggested that targeting posttranslational modifications of SHP may be an effective therapeutic strategy. Selected groups of genes could be controlled to cure a vast range of metabolic and SHP-related diseases . Overall, the huge amount of information on SHP function is currently available, making this NR essential in a number of functions involving cholesterol and bile acid metabolism, lipogenesis, glucose metabolism, steroid hormone biosynthesis, xenobiotic homeostasis/metabolism, and cell cycle.
In particular, the ability of SHP in interacting with different metabolic signaling pathways including bile acids and lipid homeostasis, fat mass, adipocytes, and obesity will be reviewed here.
2. Bile Acids and Lipid Homeostasis
The wide ability of SHP to target multiple genes in diverse signaling pathways points to the key role of SHP in various biological processes, including the metabolism of bile salts, glucose, and fatty acids. Both unique structure and functional properties account for the complexity of SHP signaling. Studies suggest that loss of SHP might positively affect cholesterol and bile acid homeostasis in pathophysiologically relevant conditions . Bile acids (BAs) are amphipatic cholesterol metabolites which are synthesized in the liver, secreted into bile, stored in the gallbladder, and secreted postprandially into the duodenum. BAs are synthesized from cholesterol, and this pathway provides the elimination of excess cholesterol in the body . Moreover, BAs should be seen as physiological detergents which, in the small intestine, are essential for the absorption, transport, and distribution of lipophilic molecules, including dietary lipids, steroids, and lipid-soluble vitamins. In the intestine, BAs undergo extensive metabolism by the intestinal microflora. A high efficient system is the enterohepatic circulation of BAs [55, 56], where more than 90–95% of BAs are returned to the liver from the terminal ileum via the portal vein. Thus, the concentration of BAs in serum, liver, and intestine is tightly regulated to prevent damage to enterohepatic tissues due to their strong detergent moiety [57–59]. The major rate-limiting step in biosynthetic pathway of BAs in humans is initiated by cholesterol 7α-hydroxylase (CYP7A1), the microsomal P450 liver enzyme, to produce two primary BAs, cholic acid, and chenodeoxycholic acid, essential in the overall balance of cholesterol homeostasis. Sterol 12α hydroxylase (CYP8B1) catalyzes the synthesis of cholic acid, a step which determines the cholic acid to CDCA ratio in the bile . Secondary bile acids (deoxycholic acid and lithocholic acid) and tertiary bile acids (ursodeoxycholic acid) in humans are produced following intestinal dehydroxylation of primary bile acids by intestinal bacteria [58, 61].
Regulation of BA biosynthesis is highly coordinated and is mediated by key NRs including the orphan receptor, liver receptor homologue-1 (LRH1; NR5A2), the hepatocyte nuclear factor 4α (HNF4α), SHP, and the bile acid receptor farnesoid X receptor (FXR; NR1H4). Thus, the activation of FXR initiates a feedback regulatory loop via induction of SHP, which suppresses LRH-1- and HNF4α-dependent expression of the two major pathway enzymes cholesterol 7hydroxylase (CYP7A1) and sterol 12 hydroxylase (CYP8B1).
The BA feedback regulation primarily occurs since BAs act as transcriptional regulators for the expression of the gene encoding CYP7A1. Both cholic acid and chenodeoxycholic acid function as endogenous ligands for the nuclear bile acid receptor FXR . FXR expression is high in the intestine and liver, the two sites where BAs reach high concentrations to activate FXR. The transcription by FXR includes heterodimerization with retinoid X receptors (RXRs) in the cytoplasm, translocation into the nucleus, and binding to DNA response elements in the regulatory regions of target genes . When the bind of BAs to FXR, SHP transcription is increased [60, 64, 65], this alteration leads to the inhibition of LRH-1 activity or HNF4α on the BA response elements (BAREs) of CYP7A1 and CYP8B1 promoters [64, 65]. In this scenario, BA synthesis is downregulated by a precise feedback regulatory mechanism, which represents the major pathway under normal physiological conditions [64–66] (Figure 3). LRH1 is also a well-known activator of Shp gene transcription [64, 65], and this step leads to an autoregulatory loop of gene expression by SHP . This step also includes the G protein pathway suppressor 2 (GPS2) interacting with FXR, LRH-1, and HNF4α to regulate CYP7A1 and CYP8B1 expression in human hepatocytes  (Table 3). A critical role in maintaining cholesterol homeostasis for CYP7A1 has been recently advocated in a model of in Cyp7a1-tg mice .
The hepatocyte nuclear factor-1α (HNF1α), which haploinsufficiency causes the Maturity-onset diabetes of the young type 3 (MODY3), also appears to modulate SHP expression via the FXR pathway. In this respect, HNF1α (−/−) mice displayed a defect in bile acid transport, increased bile acid and liver cholesterol synthesis, and impaired HDL metabolism .
A role for SHP in mediating the recruitment of mSin3A-Swi/Snf to the CYP7A1 promoter, with chromatin remodeling and gene repression, has been described. In HepG2 cells, Kemper et al.  have shown that bile acid treatment resulted in SHP-mediated recruitment of transcriptional coregulators mSin3A and Swi/Snf complex to the promoter, chromatin remodeling, and gene repression (Table 3). This is an additional mechanism involving transformation of nucleosome conformation for the repression by SHP of genes activated by various NRs. In line with such results, increased synthesis and accumulation of BAs occurs in SHP (−/−) mice, due to the loss of SHP repression and consequent derepression of the rate-limiting CYP7A1 and cholesterol 12α-hydroxylase (CYP8B1) (the rate-determining enzyme of the alternative but minor BA synthesis pathway) in the biosynthetic pathway [70–72].
Mechanisms independent of the FXR/SHP/LRH pathway might also exist, since BAs feeding to SHP (−/−) mice reduced the levels of CYP7A1 mRNA to similar levels of control mice [70, 71]. Such SHP-independent and alternative pathways include the protein kinase C/Jun N-terminal kinase (PKC/JNK) pathway , the FXR/FGFR4 (FGF receptor 4) pathway [57, 74], the cytokine/JNK pathway , the pregnane X receptor (PXR) mediated pathway , and the JNK/c-Jun signaling pathway .
Another study demonstrated, in SHP (−/−) mice on a background of 129 strain, the protection against hypercholesterolemia in three different models: an atherogenic diet, hypothyroidism, and SHP (−/−) mice intercrossed with LDLR (−/−) mice (to generate SHP/LDLR double (−/−) mice in a mixed 129-C57BL/6 background). When fed an atherogenic diet, the latter strain was almost completely resistant to diet-mediated increases in triglyceride, very low-density lipoprotein (VLDL) cholesterol, and low-density lipoprotein (LDL) cholesterol but had an increase in high-density lipoprotein (HDL) cholesterol as compared with LDLR (−/−) mice. Such results point to the protection against dyslipidemia following the inhibition of hepatic SHP expression, although no antagonist ligands have yet been identified for SHP . We have recently examined biliary lipid secretion and cholesterol gallstone formation in male SHP (−/−) and (+/+) mice before and during the feeding of a lithogenic diet for 56 days . Deletion of the Shp gene significantly increased hepatic bile salt synthesis, and doubled the increase of biliary bile salt outputs in SHP (−/−) mice than in (+/+) mice. The intestinal bile acid pool size was significantly greater in SHP (−/−) mice than in (+/+) mice. These increased BAs are efficacious ligands of FXR and can stimulate the expression of intestinal fibroblast growth factor 15 (FGF15) in mice through the FXR signaling pathway, which is consistent with the expanded bile acid pool size in SHP (−/−) mice. At 14 days on the lithogenic diet, fasting gallbladder volume was significantly larger in SHP (+/+) mice than in (−/−) mice .
Indeed, FGF15/19 (mouse and human orthologs, resp.) is another FXR gene target in the intestine and appears to contribute to the fine tuning of bile acid synthesis in the liver. Thus, a model for FXR-mediated repression of bile acid synthesis should also take into account the bile acid-mediated activation of intestinal FXR and FGF15 in the small intestine (while the FXR-SHP pathway is activated in the liver). According to the most plausible view, FGF15 acts as a hormone to signal between intestine and liver. The secreted FGF15 by the intestine circulates to the liver, likely through the portal circulation or lymph flow , and induces the activation of FGFR4 in the liver. As shown in Figure 3, the FGF15/FGFR4 pathway synergizes with SHP in vivo to repress CYP7A1 expression . In humans, a similar mechanism should involve the FGF19. Of note, activation of FXR transcription in the intestine protected the liver from cholestasis in mice by inducing FGF15 expression and reducing the hepatic pool of BA. This suggests a potential approach to reverse cholestasis in patients . Hepatic fatty acid homeostasis is also regulated by SHP since regulating these genes involves in fatty acid uptake, synthesis, and export [83–87]. In a study exploring global gene expression profiling combined with chromatin immunoprecipitation assays in transgenic mice constitutively expressing SHP in the liver, overexpression of SHP in the liver was associated with the depletion of the hepatic bile acid pool and a concomitant accumulation of triglycerides in the liver . By contrast, fat accumulation induced by a high-cholesterol or high-fat diet is prevented by the deletion of SHP [88, 89]. The pleiotropic role of SHP can also be found in the case of nonalcoholic liver steatosis since OB/SHP double (−/−) mice (a model of severe obesity and insulin resistance) became resistant to liver steatosis and showed improved insulin sensitivity .
Another interesting role for SHP emerged after it was found that BAs negatively regulate the human angiotensinogen (ANG) gene. ANG is the precursor of vasoactive octapeptide angiotensin II, and BAs act through the SHP pathway by preventing hepatocyte nuclear factor-4 (HNF4) from binding to the human ANG promoter .
3. Fat Mass, Adipocytes, and Obesity
SHP appears to play a central role in obesity. Human obesity is considered a polygenic disorder characterized by partly known abnormal molecular mechanisms resulting in increased fat mass, with an imbalance between the energy acquired from nutrients that dissipated as heat (i.e., thermogenesis). In this respect, weight stability requires a balance between calories consumed and calories expended . In adipose tissue depots, two main types of adipocytes exist, that is, brown adipocytes and white adipocytes. In several animal species, some adipose tissue sites mainly include brown adipocytes (BATs) and the other contains mainly white adipocytes (WATs). BAT dissipates chemical energy to produce heat either as a defense against cold  or as energy expenditure to compensate food intake [93, 94]. The unusual function of BAT might be better understood by considering that they share a common origin with myocytes [95, 96], and BAT was indeed considered something in between muscle and adipose tissue . BAT is deemed as the major site for sympathetic (adrenergic) mediated adaptive thermogenesis; this pathway involves the uncoupling protein-1 (UCP1). WAT is mainly implicated in the regulation of lipid storage and catabolism but also in the synthesis and secretion of adipokines [97–100]. While the percentage of young men with BAT is high, the activity of BAT is reduced in men who are overweight or obese . Thermogenesis unequivocally exists in both humans and animals, and BAT is the major site of thermogenesis which can be increased by environmental factors (i.e., adaptive thermogenesis). In both human and animal species, dietary composition, chronic cold exposure, and exercise may increase thermogenesis . As far as adipose tissue biology is concerned, SHP seems to play a distinct regulatory function in WAT, as compared with BAT. A number of experiments have focused on animal models of obesity and subtle molecular changes. SHP-deficient mice are protected against high-fat-diet-induced obesity .
Peroxisome proliferator-activated receptor (PPAR) γ coactivator-1 (PGC-1) family members are multifunctional transcriptional coregulators. PGC-1 acts as a molecular switch in several metabolic pathways. In particular, PGC-1α and PGC-1β regulate mitochondrial biogenesis, adaptive thermogenesis, fatty acid and glucose metabolism, fiber-type switching in skeletal muscle, peripheral circadian clock, and development of the heart . In particular, SHP functions as a negative regulator of energy production in BAT  because SHP is a negative regulator of PGC-1α expression in BAT. In turn, PCG-1α is a coactivator of uncoupling protein 1 (UCP1) which plays a major role in energy dissipation as heat in multilocular BAT of different animal species and humans [104–106]. Fat-specific (BAT) SHP-overexpressed transgenic mice had increased body weight and adiposity. Energy metabolism, however, was increased, and BAT cold exposure function was enhanced with activation of thermogenic genes and mitochondrial biogenesis (enhanced β1-AR gene expression and PGC1α). Compared with wild-type mice on a high-fat diet, SHP overexpression was associated with enhanced diet-induced obesity phenotype with weight gain, increased adiposity, and severe glucose intolerance. An additional feature of SHP transgenic mice was a decreased diet-induced adaptive thermogenesis, increased intake of food, and decreased physical activity . This leads to the conclusion that, although expressed at low levels in fat, activation of SHP in adipocytes has a strong effect on weight gain and diet-induced obesity . Moreover, if mechanisms linked to energy metabolism and the development of obesity are considered, SHP has distinct roles in WAT and BAT. As previously mentioned, while SHP deletion in obese leptin-deficient mice (ob/ob) prevented the development of nonalcoholic fatty liver and improved peripheral insulin sensitivity , SHP deletion did not overcome the severe obesity caused by leptin deficiency. A significant protective effect from obesity by SHP deficiency was likely associated with the low basal level of SHP expressed in fat. Adipogenesis appears to be influenced by SHP: when SHP was overexpressed in 3T3-L1 preadipocytes, cell differentiation was inhibited, as well as the accumulation of neutral lipids within the cells. Thus, SHP may act as a molecular switch governing adipogenesis. In particular, SHP appears to be a potent adipogenic suppressor, and preadipocytes are kept in an undifferentiated state through the inhibition of the adipogenic transcription factors and stimulators . Further studies will address whether the loss of SHP function results in inhibition of lipid accumulation in adipocytes, similar to what is observed in hepatocytes. In a future clinical setting, treatment of obesity might also include drugs able to mimic or stimulate the effects of SHP. Mutations in the Shp gene have also been reported in patients with lipodystrophy carrying four different polymorphisms .
SHP mutations may not be considered a common cause of severe obesity. A number of important clinical studies have examined this issue (Table 4); however, Hung et al.  in UK examined the relationships between genetic variation in SHP and weight at birth, adiposity, and insulin levels in three different populations (the Genetics of Obesity Study) GOOS, the Avon Longitudinal Study of Parents and Children (ALSPAC), and the Ely studies). In the 329 cases of severe early-onset obesity (GOOS study), two novel and rare missense mutations (R34G and R36G) were identified which might in part contribute to obesity in the probands. Furthermore, two common polymorphisms, namely, G171A (12% of subjects with higher birth weight) and −195CTGAdel (16% of subjects with lower birth weight) were found. In the ALSPAC cohort of 1,079 children, the G171A variant was associated with increased body mass index and waist circumference together with higher insulin secretion 30 minutes after glucose load. Thus, whereas mutations in the Shp gene cannot be seen as a common cause of severe human obesity, genetic variation in the Shp gene locus may influence birth weight and have effects on body size. The effect might ultimately involve insulin secretion by the negative regulation between SHP and the hepatocyte nuclear factor-4α (HFN-4α), a transcription factor involved in differentiation and function of pancreatic β-cells .
A possibility is that decreased SHP expression or function results in increased HFN-4α activity with a cascade of events, including fetal hyperinsulinemia, and increased birth weight. At a later stage, sustained hyperinsulinemia might be responsible of insulin resistance and obesity of the adult .
Mutations in the Shp gene were also associated with influence on birth weight, mild obesity, and insulin levels in the study by Nishigori et al. on 274 Japanese subjects . Mutations in several genes encoding transcription factors of the hepatocyte nuclear factor (HNF) cascade are associated with maturity-onset diabetes of the young (MODY). MODY is a monogenic form of early-onset diabetes mellitus (defective insulin secretion with normal body weight), and SHP is deemed as a plausible candidate MODY gene; this is because SHP is able to inhibit the transcriptional activity of the hepatocyte nuclear factor-4α (HFN-4α), a key member of the MODY regulatory network. Thus, further studies have looked for segregation of SHP mutations with MODY in a cohort of Japanese patients with early-onset diabetes. In this context, variants in SHP appeared to cosegregate with increased body mass index in families, thus contributing to obesity among Japanese subjects. Also, increased risk of morbidity was observed in another study from Japan, examining patients with type 2 diabetes and SHP mutations .
Major differences, however, might exist in the prevalence and function of SHP variants in different populations. Of note, the results from other Caucasian cohorts did not confirm the association between SHP mutation and obesity [113, 114]. Echwald et al. conducted an elegant study on the prevalence of SHP variants by single-strand conformational polymorphism and heteroduplex analysis among 750 Danish obese men with early-onset obesity . As control, a cohort of 795 nonobese control subjects was genotyped using PCR-RFLP. Functional analyses of the identified coding region variants were performed in both MIN6-m9 and HepG2 cell lines. Five novel variants were identified (including 3 missense variants (c.100C>G [p.R34G], c.278G>A [p.G93D], and c.415C>A [p.P139H]) and 2 silent variants (c.65C>T [p.Y22Y] and c.339G>A [p.P113P])). The previously reported  c.512G>C [p.G171A] common polymorphism was identified; however, the prevalence of functional SHP variants associated with obesity was considerably lower among Danish subjects (1 out of 750 obese, none of control subjects), compared to the prevalence observed in Japan by Nishigori et al. . Mitchell at al.  investigated SHP variants in 1927 UK subjects according to type 2 diabetes, obesity, and birth weight. Although reporting a raised body mass index among homozygous carriers of the 171A variant (<1%), this polymorphism was unlikely to be associated with all three conditions in Caucasians. Taken together, the above-mentioned studies suggest that the 171A variant might contribute only to subsets of polygenic obesity.
4. Other Functions of SHP
SHP has been hypothesized to act in glucose homeostasis via complex pathways involving the inhibition of glucocorticoid receptors (GR) in mammalian cells and the inhibition of PGC-1 gene, a coactivator of NRs important for gluconeogenic gene expression and the PGC-1-regulated phospho(enol)pyruvate carboxykinase (PEPCK) promoter. Such steps underscore a physiologically relevant role for SHP in modulating hepatic glucocorticoid action . Following the bile acid-induced induction, SHP inhibited a number of other pathways, including the HNF4α-mediated transactivation of the PEPCK and fructose biphosphate (FBP) promoters, as well as the transactivation of the glucose-6-phosphatase (G6Pase) promoter mediated by Foxo1 . The interaction between SHP inhibitory function and the 3 isoforms (α, β, and γ) of the hepatocyte nuclear factor-3 (HNF4) points to the regulatory role of SHP on gluconeogenesis . A role for SHP in insulin secretion pathway has also been reported. Mutations in hepatocyte nuclear factor 1α (HNF-1α) is associated with maturity-onset diabetes of the young type 3. This condition depends on impaired insulin secretory response in pancreatic beta cells.
Indeed, loss of HNF-1α function in HNF-1α (−/−) mice resulted in altered expression of genes involved in glucose-stimulated insulin secretion, but also insulin synthesis, and beta-cell differentiation. Pancreatic islets of HNF-1α (−/−) mice showed a distinctive reduction of SHP expression and a downregulation of the HNF4α gene expression. Since SHP appears to repress its own transcriptional activation following heterodimerization with HNF4α, a feedback autoregulatory loop between SHP and HNF4α has been hypothesized . Also, SHP likely functions as a negative regulator of pancreatic islet insulin secretion. SHP (−/−) mice were characterized by hypoinsulinemia, increased glucose-dependent response of islets, increased peripheral insulin sensitivity, and increased glycogen stores . The role played by SHP in the regulation of hepatic gluconeogenesis has also emerged in a number of additional experiments. For example, the liver of SHP (−/−) mice showed increased glycogen stores , while hepatic Shp gene expression (induced by the antidiabetic biguanide drug metformin) was associated with inhibition of hepatic gluconeogenesis. Induction of SHP was achieved via AMP-activated protein kinase (AMPK) and associated with downregulation of essential gluconeogenic enzyme genes, that is, phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) , and fructose-1,6-bisphosphatase (FBP1) .
PGC-1 gene is a coactivator of NRs, and this step is relevant for gluconeogenic gene expression. Yamagata et al.  showed that bile acid (chenodeoxycholic acid) was able to induce the downregulation of PGC-1 gene, and this mechanism involved forkhead transcription factors (Foxo1, Foxo3a, Foxo4) via a SHP-dependent manner.
Drug metabolism and detoxification might be regulated by SHP. This is also the case for excess BAs: the pregnane X receptor (PXR) induces CYP3A and inhibits CYP7α, both involved in biochemical pathways leading to the conversion of cholesterol into primary BAs, whereas CYP3A is also involved in the detoxification of toxic secondary bile acid derivatives. SHP acts as a potent repressor of PXR transactivation, and this finding suggests that PXR can act on both bile acid synthesis and elimination detoxification . Additional mechanisms involved in the SHP-dependent control of pathways of drug metabolism have been identified. The expression of genes involved with the metabolism of xenobiotics might be regulated by SHP in the spleen acting on (aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT)) AHR/ARNT heterodimers which, in turn, bind to xenobiotic response elements (XREs) at the level of specific DNA sequences . A number of genes involved in hormone and drug metabolism would be expressed (i.e., UGT16, ALDH3, CYP1A1, CYP1A2, CYP1B1, etc.). SHP also appears to downregulate the constitutive-androstane-receptor- (CAR-) mediated CYP2B1 gene expression, induced by phenobarbital to form the CAR/RXR heterodimer which, in turn, binds to 2 DR-4 sites to form the phenobarbital responsive unit in the CYP2B gene  (Table 3). One role of SHP in steroidogenesis has been identified in the testes with influence on testosterone synthesis and germ cell differentiation  and in the intestine for glucocorticoid synthesis .
A role for SHP in cell proliferation and apoptosis signaling is emerging. Depending on the cell type, SHP seems to have both inhibitory and stimulatory effects on apoptosis. However, the manipulation of SHP through the synthetic ligands adamantyl-substituted retinoid-related (ARR) compounds 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437/AHPN) and 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces apoptosis of a number of malignant cells (i.e., leukemia and breast carcinoma) both in vitro and in vivo [123, 124]. The complex mechanism implies binding of ARR and 3-Cl-AHPC to SHP with formation of a corepressor complex containing Sin3A and nuclear receptor corepressor (N-CoR) which activate local control of mitochondrial function and apoptosis, with a limiting function on tumorigenesis [17, 123] (Table 3). SHP appears to be also involved in DNA methylation and acting as a tumor suppressor, at least in the human and mouse livers [125–127]. Whether manipulation of SHP will be helpful in the treatment of hepatic and other gastrointestinal cancers is still a matter of research. The recent finding that SHP negatively regulates TLR signaling to NF-κB has raised the interest for the role of SHP in mechanisms governing innate immunity. SHP appears to negatively regulate the expression of genes encoding inflammatory molecules. Of note, direct binding of NF-κB seems to occur in resting cells, while binding of SHP to TRAF6 occurs in LPS-stimulated cells [128, 129].
5. Conclusions and Perspectives
A remarkable number of metabolic functions in the body appear to be regulated by the orphan unique NR, small heterodimer partner SHP, which targets a complex set of genes in multiple pathways as a transcriptional corepressor (Figure 4). Pathways include fatty acid metabolism, glucose homeostasis, and drug-hormone detoxification. When looking at complex mechanisms leading to some important lipidopathies, that is, obesity and liver steatosis, enlightening data about the regulatory function of SHP are provided by studies using Shp-deleted and Shp-overexpressed animal models. Most likely, a condition of Shp deficiency might counteract lipid accumulation and improve plasma lipoprotein profiles. Further studies are urgently needed to confirm that such an important metabolic regulatory mechanism of SHP is true and has high translational value. To date, however, no synthetic antagonists or agonists for SHP are available, and one should keep in mind that rather divergent and somewhat elusive data have been observed regarding the loss of SHP function in humans and rodents. Thus, careful examination of subtle SHP intrinsic functions is essential to dissect potential modulatory pathways of SHP for a variety of metabolic abnormalities but also in tumorigenesis. Moreover, identifying specific endogenous ligands and synthetic agonists of SHP will pave the way to for therapeutic intervention. The effect of synthetic ligands on SHP modulation in hepatocytes and adipocytes, for example, might represent therapeutic tools for the treatment of constituents of the metabolic syndrome, namely, hypercholesterolemia, overweight obesity, and liver steatosis.
|AF1:||Activation function 1|
|AF2:||Activation function 2|
|AHR/ARNT:||Aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT)|
|ALDH3:||Human aldehyde dehydrogenase 3 gene|
|AMPK:||AMP-activated protein kinase|
|ARR:||Adamantyl-substituted retinoid-related molecules|
|BAREs:||Bile acids response elements|
|BAT:||Brown adipose tissue|
|Brm:||Human Brahma (a catalytic component of the SWI/SNF-related chromatin-remodeling complex)|
|CAR:||Constitutive androstane receptor|
|CYP3A:||Hepatic cytochrome P-4503A|
|CYP1A1:||Cytochrome P450, family 1, subfamily A, polypeptide 1|
|CYP1A2:||Cytochrome P450, family 1, subfamily A, polypeptide 2|
|CYP1B1:||Cytochrome P450, family 1, subfamily B, polypeptide 1|
|CYP2B1:||Cytochrome P450, subfamily IIB|
|CYP7A1:||Cholesterol 7 alpha-hydroxylase|
|DAX-1:||Dosage-sensitive sex reversal adrenal hypoplasia congenita (AHC) critical region on the X chromosome, gene 1|
|DR-4:||Nuclear receptor half-site repeat|
|FGF:||Fibroblast growth factor|
|FGFR:||Fibroblast growth factor receptor|
|FISH:||Fluorescence in situ hybridization|
|Foxo:||Forkhead transcription factors|
|FXR:||Farnesoid X receptor|
|GPS2:||G protein pathway suppressor 2|
|HNF:||Hepatocyte nuclear factor|
|JNK:||Jun N-terminal kinase|
|JUN-D:||Jun family of the activator protein 1 (AP-1) transcription factor complex|
|LDLR:||Low-density lipoprotein receptor|
|LRH1:||Liver receptor homologue 1|
|3T3-L1:||Mouse embryonic fibroblast adipose-like cell line.|
|mSin3A:||Mammalian homolog of the Saccharomyces cerevisiae transcriptional corepressor Sin3p|
|N-CoR:||Nuclear receptor corepressor|
|PGC-1:||Peroxisome proliferator-activated receptor-γ (PPAR-γ) coactivator-1|
|PKC:||Protein kinase C|
|PXR:||Pregnane X receptor|
|RAR:||Retinoid acid receptor|
|RNA Pol II:||RNA polymerase II|
|RNF31||Member of the ring-between-ring (RBR) family of E3 ubiquitin ligases|
|RXR:||Retinoid X receptor|
|SHP:||Small heterodimer partner|
|SMILE:||SHP-interacting leucine zipper protein|
|SMRT:||Silencing mediator of retinoid and thyroid hormone receptor|
|SRC-1:||Steroid receptor coactivator-1|
|SWI/SNF:||SWItch/Sucrose NonFermentable (yeast nucleosome remodeling complex composed of several proteins which are products of the SWI and SNF genes)|
|USF-1:||Upstream stimulatory factor-1|
|TFIID:||Transcription initiation factor II D|
|TFIIE:||Transcription factor II E|
|UGT-16:||Uridine 5′-diphospho (UDP) glucuronosyl transferase family member|
|XREs:||Xenobiotic response elements|
|WAT:||White adipose tissue.|
Conflict of Interests
The authors declare that there is no conflict of interests.
This work was supported in part by research grants DK54012 and DK73917 (D. Q.-H. Wang) from the National Institutes of Health (US Public Health Service), FIRB 2003 RBAU01RANB002 (P. Portincasa) from the Italian Ministry of University and Research, and ORBA10ROPA from the University of Bari. P. Portincasa was a recipient of the short-term mobility grant 2005 from the Italian National Research Council (CNR). L. Bonfrate was a recipient of the travel grant for young investigators from the European Society for Clinical Investigation, 2011. Due to space limitations, the authors apologize to those whose publications related to the discussed issues could not be cited.
- J. C. Ourlin, F. Lasserre, T. Pineau et al., “The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity,” Molecular Endocrinology, vol. 17, no. 9, pp. 1693–1703, 2003.
- H. Gronemeyer, J. Å. Gustafsson, and V. Laudet, “Principles for modulation of the nuclear receptor superfamily,” Nature Reviews Drug Discovery, vol. 3, no. 11, pp. 950–964, 2004.
- D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear receptor super-family: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995.
- D. J. Mangelsdorf and R. M. Evans, “The RXR heterodimers and orphan receptors,” Cell, vol. 83, no. 6, pp. 841–850, 1995.
- K. Pardee, A. S. Necakov, and H. Krause, “Nuclear receptors: small molecule sensors that coordinate growth, metabolism and reproduction,” Subcellular Biochemistry, vol. 52, pp. 123–153, 2011.
- H. Gronemeyer and D. Moras, “How to finger DNA,” Nature, vol. 375, no. 6528, pp. 190–191, 1995.
- E. Lalli and P. Sassone-Corsi, “DAX-1, an unusual orphan receptor at the crossroads of steroidogenic function and sexual differentiation,” Molecular Endocrinology, vol. 17, no. 8, pp. 1445–1453, 2003.
- Y. S. Lee, D. Chanda, J. Sim, Y. Y. Park, and H. S. Choi, “Structure and function of the atypical orphan nuclear receptor small heterodimer partner,” International Review of Cytology, vol. 261, pp. 117–158, 2007.
- F. Muscatelli, T. M. Strom, A. P. Walker et al., “Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congentia and hypogonadotropic hypogonadism,” Nature, vol. 372, no. 6507, pp. 672–676, 1994.
- W. Seol, H. S. Choi, and D. D. Moore, “An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors,” Science, vol. 272, no. 5266, pp. 1336–1339, 1996.
- E. Zanaria, F. Muscatelli, B. Bardoni et al., “An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita,” Nature, vol. 372, no. 6507, pp. 635–641, 1994.
- A. Båvner, S. Sanyal, J.-Å. Gustafsson, and E. Treuter, “Transcriptional corepression by SHP: molecular mechanisms and physiological consequences,” Trends in Endocrinology and Metabolism, vol. 16, no. 10, pp. 478–488, 2005.
- J. Miao, S.-E. Choi, S. M. Seok et al., “Ligand-dependent regulation of the activity of the orphan nuclear receptor, small heterodimer partner (SHP), in the repression of bile acid biosynthetic CYP7A1 and CYP8B1 genes,” Molecular Endocrinology, vol. 25, no. 7, pp. 1159–1169, 2011.
- L. Farhana, M. I. Dawson, M. Leid et al., “Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor,” Cancer Research, vol. 67, no. 1, pp. 318–325, 2007.
- D. Chanda, J. H. Park, and H. S. Choi, “Molecular basis of endocrine regulation by orphan nuclear receptor small heterodimer partner,” Endocrine Journal, vol. 55, no. 2, pp. 253–268, 2008.
- V. Giguere, “Orphan nuclear receptors: from gene to function,” Endocrine Reviews, vol. 20, no. 5, pp. 689–725, 1999.
- Y. Zhang, C. H. Hagedorn, and L. Wang, “Role of nuclear receptor SHP in metabolism and cancer,” Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 893–908, 2011.
- H. K. Lee, Y. K. Lee, S. H. Park et al., “Structure and expression of the orphan nuclear receptor SHP gene,” Journal of Biological Chemistry, vol. 273, no. 23, pp. 14398–14402, 1998.
- A. L. Bookout, Y. Jeong, M. Downes, R. T. Yu, R. M. Evans, and D. J. Mangelsdorf, “Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network,” Cell, vol. 126, no. 4, pp. 789–799, 2006.
- X. Yang, M. Downes, R. T. Yu et al., “Nuclear receptor expression links the circadian clock to metabolism,” Cell, vol. 126, no. 4, pp. 801–810, 2006.
- L. Johansson, A. Båvner, J. S. Thomsen, M. Färnegårdh, J. Å. Gustafsson, and E. Treuter, “The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors,” Molecular and Cellular Biology, vol. 20, no. 4, pp. 1124–1133, 2000.
- L. J. Borgius, K. R. Steffensen, J. Å. Gustafsson, and E. Treuter, “Glucocorticoid signaling is perturbed by the atypical orphan receptor and corepressor SHP,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49761–49766, 2002.
- J. Gobinet, G. Auzou, J. C. Nicolas, C. Sultan, and S. Jalaguier, “Characterization of the interaction between androgen receptor and a new transcriptional inhibitor, SHP,” Biochemistry, vol. 40, no. 50, pp. 15369–15377, 2001.
- W. Seol, M. Chung, and D. D. Moore, “Novel receptor interaction and repression domains in the orphan receptor SHP,” Molecular and Cellular Biology, vol. 17, no. 12, pp. 7126–7131, 1997.
- Y. B. Xie, B. Nedumaran, and H. S. Choi, “Molecular characterization of SMILE as a novel corepressor of nuclear receptors,” Nucleic Acids Research, vol. 37, no. 12, pp. 4100–4115, 2009.
- Y. B. Xie, J. H. Park, D. K. Kim et al., “Transcriptional corepressor SMILE recruits SIRT1 to inhibit nuclear receptor estrogen receptor-related receptor γ transactivation,” Journal of Biological Chemistry, vol. 284, no. 42, pp. 28762–28774, 2009.
- H. J. Kim, J. Y. Kim, J. Y. Kim et al., “Differential regulation of human and mouse orphan nuclear receptor small heterodimer partner promoter by sterol regulatory element binding protein-1,” Journal of Biological Chemistry, vol. 279, no. 27, pp. 28122–28131, 2004.
- D. Chanda, T. Li, K.-H. Song et al., “Hepatocyte growth factor family negatively regulates hepatic gluconeogenesis via induction of orphan nuclear receptorsmall heterodimer partner in primary hepatocytes,” Journal of Biological Chemistry, vol. 284, no. 42, pp. 28510–28521, 2009.
- J. Cui, L. Huang, A. Zhao et al., “Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump,” Journal of Biological Chemistry, vol. 278, no. 12, pp. 10214–10220, 2003.
- G. Rizzo, B. Renga, E. Antonelli, D. Passeri, R. Pellicciari, and S. Fiorucci, “The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes,” Molecular Pharmacology, vol. 68, no. 2, pp. 551–558, 2005.
- K. Isoda, S. Sawada, M. Ayaori et al., “Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice,” Journal of Biological Chemistry, vol. 280, no. 8, pp. 7002–7009, 2005.
- M. G. Yeo, Y. G. Yoo, H. S. Choi, Y. K. Pak, and M. O. Lee, “Negative cross-talk between Nur77 and small heterodimer partner and its role in apoptotic cell death of hepatoma cells,” Molecular Endocrinology, vol. 19, no. 4, pp. 950–963, 2005.
- E. Kanaya, T. Shiraki, and H. Jingami, “The nuclear bile acid receptor FXR is activated by PGC-1α in a ligand-dependent manner,” Biochemical Journal, vol. 382, no. 3, pp. 913–921, 2004.
- J. M. Del Bas, J. Fernández-Larrea, M. Blay et al., “Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats,” FASEB Journal, vol. 19, no. 3, pp. 479–481, 2005.
- S. Ito, T. Fujimori, A. Furuya, J. Satoh, Y. Nabeshima, and Y.-I. Nabeshima, “Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho,” Journal of Clinical Investigation, vol. 115, no. 8, pp. 2202–2208, 2005.
- M. J. Evans, K. Lai, L. J. Shaw, D. C. Harnish, and C. C. Chadwick, “Estrogen receptor α inhibits IL-1β induction of gene expression in the mouse liver,” Endocrinology, vol. 143, no. 7, pp. 2559–2570, 2002.
- Y. Y. Park, H. J. Kim, J. Y. Kim et al., “Differential role of the loop region between helices H6 and H7 within the orphan nuclear receptors small heterodimer partner and DAX-1,” Molecular Endocrinology, vol. 18, no. 5, pp. 1082–1095, 2004.
- A. Oiwa, T. Kakizawa, T. Miyamoto et al., “Synergistic regulation of the mouse orphan nuclear receptor SHP gene promoter by CLOCK-BMAL1 and LRH-1,” Biochemical and Biophysical Research Communications, vol. 353, no. 4, pp. 895–901, 2007.
- Y. B. Xie, O. H. Lee, B. Nedumaran et al., “SMILE, a new orphan nuclear receptor SHP-interacting protein, regulates SHP-repressed estrogen receptor transactivation,” Biochemical Journal, vol. 416, no. 3, pp. 463–473, 2008.
- J. H. Suh, J. Huang, Y. Y. Park et al., “Orphan nuclear receptor small heterodimer partner inhibits transforming growth factor-β signaling by repressing Smad3 transactivation,” Journal of Biological Chemistry, vol. 281, no. 51, pp. 39169–39178, 2006.
- C. M. Klinge, S. C. Jernigan, K. E. Risinger et al., “Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT),” Archives of Biochemistry and Biophysics, vol. 390, no. 1, pp. 64–70, 2001.
- D. Chanda, Y. B. Xie, and H. S. Choi, “Transcriptional corepressor shp recruits sirt1 histone deacetylase to inhibit LRH-1 transactivation,” Nucleic Acids Research, vol. 38, no. 14, pp. 4607–4619, 2010.
- A. Ehrlund, E. H. Anthonisen, N. Gustafsson et al., “E3 ubiquitin ligase RNF31 cooperates with DAX-1 in transcriptional repression of steroidogenesis,” Molecular and Cellular Biology, vol. 29, no. 8, pp. 2230–2242, 2009.
- Y. S. Kim, C. Y. Han, S. W. Kim et al., “The orphan nuclear receptor small heterodimer partner as a novel coregulator of nuclear factor-κB in oxidized low density lipoprotein-treated macrophage cell line RAW 264.7,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 33736–33740, 2001.
- H. Nishizawa, K. Yamagata, I. Shimomura et al., “Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor γ transactivation,” Journal of Biological Chemistry, vol. 277, no. 2, pp. 1586–1592, 2002.
- A. Kassam, J. P. Capone, and R. A. Rachubinski, “The short heterodimer partner receptor differentially modulates peroxisome proliferator-activated receptor α-mediated transcription from the peroxisome proliferator-response elements of the genes encoding the peroxisomal β-oxidation enzymes acyl-CoA oxidase and hydratase-dehydrogenase,” Molecular and Cellular Endocrinology, vol. 176, no. 1-2, pp. 49–56, 2001.
- Y. K. Lee, H. Dell, D. H. Dowhan, M. Hadzopoulou-Cladaras, and D. D. Moore, “The orphan nuclear receptor SHP inhibits hepatocyte nuclear factor 4 and retinoid X receptor transactivation: two mechanisms for repression,” Molecular and Cellular Biology, vol. 20, no. 1, pp. 187–195, 2000.
- Y. K. Lee and D. D. Moore, “Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner,” Journal of Biological Chemistry, vol. 277, no. 4, pp. 2463–2467, 2002.
- L. Johansson, J. S. Thomsen, A. E. Damdimopoulos, G. Spyrou, J. A. Gustafsson, and E. Treuter, “The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ERα and ERβ,” Journal of Biological Chemistry, vol. 274, no. 1, pp. 345–353, 1999.
- J. K. Kemper, H. Kim, J. Miao, S. Bhalla, and Y. Bae, “Role of an mSin3A-Swi/Snf chromatin remodeling complex in the feedback repression of bile acid biosynthesis by SHP,” Molecular and Cellular Biology, vol. 24, no. 17, pp. 7707–7719, 2004.
- J. Y. Kim, H. J. Kim, K. T. Kim et al., “Orphan nuclear receptor small heterodimer partner represses hepatocyte nuclear factor 3/foxa transactivation via inhibition of its DNA binding,” Molecular Endocrinology, vol. 18, no. 12, pp. 2880–2894, 2004.
- S. Fiorucci, E. Antonelli, G. Rizzo et al., “The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis,” Gastroenterology, vol. 127, no. 5, pp. 1497–1512, 2004.
- D. Kanamaluru, Z. Xiao, S. Fang et al., “Arginine methylation by PRMT5 at a naturally occurring mutation site Is critical for liver metabolic regulation by small heterodimer partner,” Molecular and Cellular Biology, vol. 31, no. 7, pp. 1540–1550, 2011.
- M. O. Hoeke, J. R. M. Plass, J. Heegsma et al., “Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters,” Hepatology, vol. 49, no. 1, pp. 151–159, 2009.
- S. Sherlock and J. Dooley, Diseases of the Liver and Biliary System, Blackwell Science, Oxford, UK, 2002.
- J. Y. Chiang, “Regulation of bile acid synthesis,” Frontiers in Bioscience, vol. 3, pp. d176–d193, 1998.
- T. Inagaki, M. Choi, A. Moschetta et al., “Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis,” Cell Metabolism, vol. 2, no. 4, pp. 217–225, 2005.
- C. V. Diogo, I. Grattagliano, P. J. Oliveira, L. Bonfrate, and P. Portincasa, “Re-wiring the circuit: mitochondria as a pharmacological target in liver disease,” Current Medicinal Chemistry, vol. 18, no. 35, pp. 5448–5465, 2011.
- I. Grattagliano, S. Russmann, C. Diogo et al., “Mitochondria in chronic liver disease,” Current Drug Targets, vol. 12, no. 6, pp. 879–893, 2011.
- J. Y. L. Chiang, “Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms,” Journal of Hepatology, vol. 40, no. 3, pp. 539–551, 2004.
- D. F. Jelinek, S. Andersson, C. A. Slaughter, and D. W. Russell, “Cloning and regulation of cholesterol 7α-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis,” Journal of Biological Chemistry, vol. 265, no. 14, pp. 8190–8197, 1990.
- D. J. Parks, S. G. Blanchard, R. K. Bledsoe et al., “Bile acids: natural ligands for an orphan nuclear receptor,” Science, vol. 284, no. 5418, pp. 1365–1368, 1999.
- B. A. Laffitte, H. R. Kast, C. M. Nguyen, A. M. Zavacki, D. D. Moore, and P. A. Edwards, “Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor,” Journal of Biological Chemistry, vol. 275, no. 14, pp. 10638–10647, 2000.
- B. Goodwin, S. A. Jones, R. R. Price et al., “A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis,” Molecular Cell, vol. 6, no. 3, pp. 517–526, 2000.
- T. T. Lu, M. Makishima, J. J. Repa et al., “Molecular basis for feedback regulation of bile acid synthesis by nuclear receptos,” Molecular Cell, vol. 6, no. 3, pp. 507–515, 2000.
- D. S. Ory, “Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home?” Circulation Research, vol. 95, no. 7, pp. 660–670, 2004.
- S. Sanyal, A. Båvner, A. Haroniti et al., “Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 40, pp. 15665–15670, 2007.
- T. Li, M. Matozel, S. Boehme et al., “Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis,” Hepatology, vol. 53, no. 3, pp. 996–1006, 2011.
- D. Q. Shih, M. Bussen, E. Sehayek et al., “Hepatocyte nuclear factor-1α is an essential regulator of bile acid and plasma cholesterol metabolism,” Nature Genetics, vol. 27, no. 4, pp. 375–382, 2001.
- L. Wang, Y. K. Lee, D. Bundman et al., “Redundant pathways for negative feedback regulation of bile acid production,” Developmental Cell, vol. 2, no. 6, pp. 721–731, 2002.
- T. A. Kerr, S. Saeki, M. Schneider et al., “Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis,” Developmental Cell, vol. 2, no. 6, pp. 713–720, 2002.
- S. Khurana, J.-P. Raufman, and T. L. Pallone, “Bile acids regulate cardiovascular function,” Clinical and Translational Science, vol. 4, no. 3, pp. 210–218, 2011.
- R. T. Stravitz, Y. P. Rao, Z. R. Vlahcevic et al., “Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7α-hydroxylase,” American Journal of Physiology, vol. 271, no. 2, pp. G293–G303, 1996.
- J. A. Holt, G. Luo, A. N. Billin et al., “Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis,” Genes and Development, vol. 17, no. 13, pp. 1581–1591, 2003.
- E. De Fabiani, N. Mitro, A. C. Anzulovich, A. Pinelli, G. Galli, and M. Crestani, “The negative effects of bile acids and tumor necrosis factor-α on the transcription of cholesterol 7α-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors,” Journal of Biological Chemistry, vol. 276, no. 33, pp. 30708–30716, 2001.
- T. Li and J. Y. L. Chiang, “Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7α-hydroxylase gene transcription,” American Journal of Physiology, vol. 288, no. 51, pp. G74–G84, 2005.
- T. Li, A. Jahan, and J. Y. L. Chiang, “Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway in human liver cells,” Hepatology, vol. 43, no. 6, pp. 1202–1210, 2006.
- H. B. Hartman, K. D. Lai, and M. J. Evans, “Loss of small heterodimer partner expression in the liver protects against dyslipidemia,” Journal of Lipid Research, vol. 50, no. 2, pp. 193–203, 2009.
- H. H. Wang, P. Portincasa, N. Mendez-Sanchez, M. Uribe, and D. Q. H. Wang, “Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones,” Gastroenterology, vol. 134, no. 7, pp. 2101–2110, 2008.
- H. H. Wang, P. Portincasa, M. Liu, and D. Q. H. Wang, “Rapid postprandial gallbladder refilling and increased turnover of bile prevent cholesterol crystallization in small heterodimer partner (SHP) knockout mice. DDW 2011, Chicago, USA,” Gastroenterology, vol. 140, no. 5, pp. S67–S68, 2011.
- I. Bjorkhem, R. Blomstrand, A. Lewenhaupt, and L. Svensson, “Effect of lymphatic drainage on 7α-hydroxylation of cholesterol in rat liver,” Biochemical and Biophysical Research Communications, vol. 85, no. 2, pp. 532–540, 1978.
- S. Modica, M. Petruzzelli, E. Bellafante, et al., “Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis,” Gastroenterology, vol. 142, no. 2, pp. 355–365, 2011.
- M. Watanabe, S. M. Houten, L. Wang et al., “Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c,” Journal of Clinical Investigation, vol. 113, no. 10, pp. 1408–1418, 2004.
- K. Boulias, N. Katrakili, K. Bamberg, P. Underhill, A. Greenfield, and I. Talianidis, “Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP,” EMBO Journal, vol. 24, no. 14, pp. 2624–2633, 2005.
- K. E. Matsukuma, L. Wang, M. K. Bennett, and T. F. Osborne, “A key role for orphan nuclear receptor liver receptor homologue-1 in activation of fatty acid synthase promoter by liver X receptor,” Journal of Biological Chemistry, vol. 282, no. 28, pp. 20164–20171, 2007.
- J. Huang, J. Iqbal, P. K. Saha et al., “Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver,” Hepatology, vol. 46, no. 1, pp. 147–157, 2007.
- P. Delerive, C. M. Galardi, J. E. Bisi, E. Nicodeme, and B. Goodwin, “Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription,” Molecular Endocrinology, vol. 18, no. 10, pp. 2378–2387, 2004.
- L. Wang, Y. Han, C. S. Kim, Y. K. Lee, and D. D. Moore, “Resistance of SHP-null mice to bile acid-induced liver damage,” Journal of Biological Chemistry, vol. 278, no. 45, pp. 44475–44481, 2003.
- L. Wang, J. Liu, P. Saha et al., “The orphan nuclear receptor SHP regulates PGC-1α expression and energy production in brown adipocytes,” Cell Metabolism, vol. 2, no. 4, pp. 227–238, 2005.
- Y. Shimamoto, J. Ishida, K. Yamagata et al., “Inhibitory effect of the small heterodimer partner on hepatocyte nuclear factor-4 mediates bile acid-induced repression of the human angiotensinogen gene,” Journal of Biological Chemistry, vol. 279, no. 9, pp. 7770–7776, 2004.
- D. Mozaffarian, T. Hao, E. B. Rimm, W. C. Willett, and F. B. Hu, “Changes in diet and lifestyle and long-term weight gain in women and men,” New England Journal of Medicine, vol. 364, no. 25, pp. 2392–2404, 2011.
- S. Kajimura, P. Seale, and B. M. Spiegelman, “Transcriptional control of brown fat development,” Cell Metabolism, vol. 11, no. 4, pp. 257–262, 2010.
- N. J. Rothwell and M. J. Stock, “Effect of chronic food restriction on energy balance, thermogenic capacity, and brown-adipose-tissue activity in the rat,” Bioscience Reports, vol. 2, no. 8, pp. 543–549, 1982.
- N. J. Rothwell and M. J. Stock, “Effects of feeding a palatable “cafeteria” diet on energy balance in young and adult lean (+/?) Zucker rats,” British Journal of Nutrition, vol. 47, no. 3, pp. 461–471, 1982.
- B. Cannon and J. Nedergaard, “Developmental biology: neither fat nor flesh,” Nature, vol. 454, no. 7207, pp. 947–948, 2008.
- P. Seale, B. Bjork, W. Yang et al., “PRDM16 controls a brown fat/skeletal muscle switch,” Nature, vol. 454, no. 7207, pp. 961–967, 2008.
- M. Klingenspor, “Cold-induced recruitment of brown adipose tissue thermogenesis,” Experimental Physiology, vol. 88, no. 1, pp. 141–148, 2003.
- P. Trayhurn, “Adipose tissue in obesity—an inflammatory issue,” Endocrinology, vol. 146, no. 3, pp. 1003–1005, 2005.
- P. Trayhurn and I. S. Wood, “Signalling role of adipose tissue: adipokines and inflammation in obesity,” Biochemical Society Transactions, vol. 33, no. 5, pp. 1078–1081, 2005.
- I. S. Wood, B. Wang, J. R. Jenkins, and P. Trayhurn, “The pro-inflammatory cytokine IL-18 is expressed in human adipose tissue and strongly upregulated by TNFα in human adipocytes,” Biochemical and Biophysical Research Communications, vol. 337, no. 2, pp. 422–429, 2005.
- W. D. Van Marken Lichtenbelt, J. W. Vanhommerig, N. M. Smulders et al., “Cold-activated brown adipose tissue in healthy men,” New England Journal of Medicine, vol. 360, no. 15, pp. 1500–1508, 2009.
- B. B. Lowell and B. M. Spiegelman, “Towards a molecular understanding of adaptive thermogenesis,” Nature, vol. 404, no. 6778, pp. 652–660, 2000.
- C. Liu and J. D. Lin, “PGC-1 coactivators in the control of energy metabolism,” Acta Biochimica et Biophysica Sinica, vol. 43, no. 4, pp. 248–257, 2011.
- J. A. Stuart, S. Cadenas, M. B. Jekabsons, D. Roussel, and M. D. Brand, “Mitochondrial proton leak and the uncoupling protein 1 homologues,” Biochimica et Biophysica Acta, vol. 1504, no. 1, pp. 144–158, 2001.
- G. Garruti and D. Ricquier, “Analysis of uncoupling protein and its mRNA in adipose tissue deposits of adult humans,” International Journal of Obesity, vol. 16, no. 5, pp. 383–390, 1992.
- F. Bouillaud, F. Villarroya, E. Hentz, S. Raimbault, A. M. Cassard, and D. Ricquier, “Detection of brown adipose tissue uncoupling protein mRNA in adult patients by a human genomic probe,” Clinical Science, vol. 75, no. 1, pp. 21–27, 1988.
- I. Tabbi-Anneni, R. Cooksey, V. Gunda et al., “Overexpression of nuclear receptor SHP in adipose tissues affects diet-induced obesity and adaptive thermogenesis,” American Journal of Physiology, vol. 298, no. 5, pp. E961–E970, 2010.
- G. Song, K. Park, and L. Wang, “Gene expression profiling reveals a diverse array of pathways inhibited by nuclear receptor SHP during adipogenesis,” International Journal of Clinical and Experimental Pathology, vol. 2, no. 3, pp. 275–285, 2009.
- H. Cao and R. A. Hegele, “Identification of polymorphisms in the human SHP1 gene,” Journal of Human Genetics, vol. 47, no. 8, pp. 445–447, 2002.
- C. C. C. Hung, I. S. Farooqi, K. Ong et al., “Contribution of variants in the small heterodimer partner gene to birthweight, adiposity, and insulin levels: mutational analysis and association studies in multiple populations,” Diabetes, vol. 52, no. 5, pp. 1288–1291, 2003.
- H. Nishigori, H. Tomura, N. Tonooka et al., “Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 2, pp. 575–580, 2001.
- M. Enya, Y. Horikawa, E. Kuroda et al., “Mutations in the small heterodimer partner gene increase morbidity risk in Japanese type 2 diabetes patients,” Human Mutation, vol. 29, no. 11, pp. E271–E277, 2008.
- S. M. S. Mitchell, M. N. Weedon, K. R. Owen et al., “Genetic variation in the small heterodimer partner gene and young-onset type 2 diabetes, obesity, and birth weight in U.K. subjects,” Diabetes, vol. 52, no. 5, pp. 1276–1279, 2003.
- S. M. Echwald, K. L. Andersen, T. I. A. Sørensen et al., “Mutation analysis of NROB2 among 1545 danish men identifies a novel c.278G > a (p.G93D) variant with reduced functional activity,” Human Mutation, vol. 24, no. 5, pp. 381–387, 2004.
- K. Yamagata, H. Daitoku, Y. Shimamoto et al., “Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1,” Journal of Biological Chemistry, vol. 279, no. 22, pp. 23158–23165, 2004.
- D. Q. Shih, S. Screenan, K. N. Munoz et al., “Loss of HNF-1α function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism,” Diabetes, vol. 50, no. 7-12, pp. 2472–2480, 2001.
- L. Wang, J. Huang, P. Saha et al., “Orphan receptor small heterodimer partner is an important mediator of glucose homeostasis,” Molecular Endocrinology, vol. 20, no. 11, pp. 2671–2681, 2006.
- Y. D. Kim, K. G. Park, Y. S. Lee et al., “Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP,” Diabetes, vol. 57, no. 2, pp. 306–314, 2008.
- K. Yamagata, K. Yoshimochi, H. Daitoku, K. Hirota, and A. Fukamizu, “Bile acid represses the peroxisome proliferator-activated receptor-γ coactivator-1 promoter activity in a small heterodimer partner-dependent manner,” International Journal of Molecular Medicine, vol. 19, no. 5, pp. 751–756, 2007.
- Y. Bae, J. K. Kemper, and B. Kemper, “Repression of CAR-mediated transactivation of CYP2B genes by the orphan nuclear receptor, short heterodimer partner (SHP),” DNA and Cell Biology, vol. 23, no. 2, pp. 81–91, 2004.
- D. H. Volle, R. Duggavathi, B. C. Magnier et al., “The small heterodimer partner is a gonadal gatekeeper of sexual maturation in male mice,” Genes and Development, vol. 21, no. 3, pp. 303–315, 2007.
- M. Mueller, A. Atanasov, I. Cima, N. Corazza, K. Schoonjans, and T. Brunner, “Differential regulation of glucocorticoid synthesis in murine intestinal epithelial versus adrenocortical cell lines,” Endocrinology, vol. 148, no. 3, pp. 1445–1453, 2007.
- Y. Zhang and L. Wang, “Nuclear receptor small heterodimer partner in apoptosis signaling and liver cancer,” Cancers, vol. 3, no. 1, pp. 198–212, 2011.
- Y. Zhang, J. Soto, K. Park et al., “Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth,” Molecular and Cellular Biology, vol. 30, no. 6, pp. 1341–1356, 2010.
- Y. Y. Park, H. S. Choi, and J. S. Lee, “Systems-level analysis of gene expression data revealed NR0B2/SHP as potential tumor suppressor in human liver cancer,” Molecules and Cells, vol. 30, no. 5, pp. 485–491, 2010.
- Y. Zhang, P. Xu, K. Park, Y. Choi, D. D. Moore, and L. Wang, “Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation,” Hepatology, vol. 48, no. 1, pp. 289–298, 2008.
- N. He, K. Park, Y. Zhang, J. Huang, S. Lu, and L. Wang, “Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth,” Gastroenterology, vol. 134, no. 3, pp. 793–802, 2008.
- J.-M. Yuk, D.-M. Shin, H.-M. Lee et al., “The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors,” Nature Immunology, vol. 12, no. 8, pp. 742–751, 2011.
- R. Beyaert, “SHP works a double shift to control TLR signaling,” Nature Immunology, vol. 12, no. 8, pp. 725–727, 2011.
- A. I. Shulman and D. J. Mangelsdorf, “Retinoid X receptor heterodimers in the metabolic syndrome,” New England Journal of Medicine, vol. 353, no. 6, pp. 604–615, 2005.
- L. Wang, “Role of small heterodimer partner in lipid homeostasis and its potential as a therapeutic target for obesity,” Clinical Lipidology, vol. 5, no. 4, pp. 445–448, 2010.
- T. Nishimaki-Mogami, M. Une, T. Fujino et al., “Identification of intermediates in the bile acid synthetic pathway as ligands for the farnesoid X receptor,” Journal of Lipid Research, vol. 45, no. 8, pp. 1538–1545, 2004.
- S. Sanyal, J. Y. Kim, H. J. Kim et al., “Differential regulation of the orphan nuclear receptor Small Heterodimer Partner (SHP) gene promoter by orphan nuclear receptor ERR isoforms,” Journal of Biological Chemistry, vol. 277, no. 3, pp. 1739–1748, 2002.
- K. Lai, D. C. Harnish, and M. J. Evans, “Estrogen receptor α regulates expression of the orphan receptor small heterodimer partner,” Journal of Biological Chemistry, vol. 278, no. 38, pp. 36418–36429, 2003.
- B. Goodwin, M. A. Watson, H. Kim, J. Miao, J. K. Kemper, and S. A. Kliewer, “Differential regulation of rat and human CYP7A 1 by the nuclear oxysterol receptor liver X receptor-α,” Molecular Endocrinology, vol. 17, no. 3, pp. 386–394, 2003.
- Y. K. Lee, K. L. Parker, H. S. Choi, and D. D. Moore, “Activation of the promoter of the orphan receptor SHP by orphan receptors that bind DNA as monomers,” Journal of Biological Chemistry, vol. 274, no. 30, pp. 20869–20873, 1999.
- H.-i. Kim, Y.-K. Koh, T.-H. Kim et al., “Transcriptional activation of SHP by PPAR-γ in liver,” Biochemical and Biophysical Research Communications, vol. 360, no. 2, pp. 301–306, 2007.
- H. J. Kim, J. Y. Kim, Y. Y. Park, and H. S. Choi, “Synergistic activation of the human orphan nuclear receptor SHP gene promoter by basic helix-loop-helix protein E2A and orphan nuclear receptor SF-1,” Nucleic Acids Research, vol. 31, no. 23, pp. 6860–6872, 2003.
- S. Gupta, R. T. Stravitz, P. Dent, and P. B. Hylemon, “Down-regulation of cholesterol 7α-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 15816–15822, 2001.
- Y. H. Choi, M. J. Park, K. W. Kim, H. C. Lee, Y. H. Choi, and J. Cheong, “The orphan nuclear receptor SHP is involved in monocytic differentiation, and its expression is increased by c-Jun,” Journal of Leukocyte Biology, vol. 76, no. 5, pp. 1082–1088, 2004.
- A. K. Iyer, Y. H. Zhang, and E. R. B. McCabe, “Dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (DAX1) (NR0B1) and Small Heterodimer Partner (SHP) (NR0B2) form homodimers individually, as well as DAX1-SHP heterodimers,” Molecular Endocrinology, vol. 20, no. 10, pp. 2326–2342, 2006.
- A. K. Iyer, Y. H. Zhang, and E. R. B. McCabe, “LXXLL motifs and AF-2 domain mediate SHP (NR0B2) homodimerization and DAX1 (NR0B1)-DAX1A heterodimerization,” Molecular Genetics and Metabolism, vol. 92, no. 1-2, pp. 151–159, 2007.
- C. M. Klinge, S. C. Jernigan, and K. E. Risinger, “The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells,” Endocrinology, vol. 143, no. 3, pp. 853–867, 2002.
- C. Brendel, K. Schoonjans, O. A. Botrugno, E. Treuter, and J. Auwerx, “The small heterodimer partner interacts with the liver X receptor α and represses its transcriptional activity,” Molecular Endocrinology, vol. 16, no. 9, pp. 2065–2076, 2002.
- S. Kress and W. F. Greenlee, “Cell-specific regulation of human CYP1A1 and CYP1B1 genes,” Cancer Research, vol. 57, no. 7, pp. 1264–1269, 1997.
- F. J. Naya, C. M. M. Stellrecht, and M. J. Tsai, “Tissue-specific regulation of the insulin gene by a novel basic helix- loop-helix transcription factor,” Genes and Development, vol. 9, no. 8, pp. 1009–1019, 1995.
- J. E. Lee, S. M. Hollenberg, L. Snider, D. L. Turner, N. Lipnick, and H. Weintraub, “Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein,” Science, vol. 268, no. 5212, pp. 836–844, 1995.
- J. Y. Kim, K. Chu, H. J. Kim et al., “Orphan nuclear receptor small heterodimer partner, a novel corepressor for a basic helix-loop-helix transcription factor BETA2/NeuroD,” Molecular Endocrinology, vol. 18, no. 4, pp. 776–790, 2004.
- M. J. Park, H. J. Kong, H. Y. Kim, H. H. Kim, J. H. Kim, and J. H. Cheong, “Transcriptional repression of the gluconeogenic gene PEPCK by the orphan nuclear receptor SHP through inhibitory interaction with C/EBPα,” Biochemical Journal, vol. 402, no. 3, pp. 567–574, 2007.
- A. Båvner, L. Johansson, G. Toresson, J. Å. Gustafsson, and E. Treuter, “A transcriptional inhibitor targeted by the atypical orphan nuclear receptor SHP,” EMBO Reports, vol. 3, no. 5, pp. 478–484, 2002.
- K. Boulias and I. Talianidis, “Functional role of G9a-induced histone methylation in small heterodimer partner-mediated transcriptional repression,” Nucleic Acids Research, vol. 32, no. 20, pp. 6096–6103, 2004.
- S. Fang, J. Miao, L. Xiang, B. Ponugoti, E. Treuter, and J. K. Kemper, “Coordinated recruitment of histone methyltransferase G9a and other chromatin-modifying enzymes in SHP-mediated regulation of hepatic bile acid metabolism,” Molecular and Cellular Biology, vol. 27, no. 4, pp. 1407–1424, 2007.
- G. Song and L. Wang, “Nuclear receptor SHP activates miR-206 expression via a cascade dual inhibitory mechanism,” PLoS ONE, vol. 4, no. 9, Article ID e6880, 2009.